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Summary: 
Epstein-Barr virus (EBV) latent proteins exert anti-apoptotic effects on 
EBV-transformed lymphoid cells by down-regulating Bim, p16
INK4A
 and p21
WAF1
. 
However, the potential therapeutic effects of targeting these anti-apoptotic 
mechanisms remain unexplored. Here, we tested both in vitro and in vivo effects of 
the combination of histone deacetylase (HDAC) and proteasome inhibitors on the 
apoptosis of six endemic Burkitt’s lymphoma (BL) lines of different latency patterns 
(types I and III and Wp-restricted) and three lymphoblastoid cell lines (LCLs). We 
found that the combination of HDAC and proteasome inhibitors (e.g. 
SAHA/bortezomib) synergistically induced the killing of Wp-restricted and latency III 
BL and LCLs but not latency I BL cells. The synergistic killing was due to apoptosis, 
as evidenced by the high percentage of annexin V positivity and strong cleavage of 
PARP and caspase-3. Concomitantly, SAHA/bortezomib up-regulated the expression 
of p16
INK4A
 and p21
WAF1
 but did not affect the level of Bim or BHRF1 (viral 
homologue of Bcl2). The apoptotic effects were dependent on reactive oxygen species 
generation. Furthermore, SAHA/bortezomib suppressed the growth of Wp-restricted 
BL xenografts in nude mice. This study provides the rationale to test the novel 
application of SAHA/bortezomib on the treatment of EBV-associated Wp-restricted 
BL and post-transplant lymphoproliferative disorder.
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Introduction 
Epstein-Barr virus (EBV) establishes life-long latent infections in normal human 
B cells and is closely associated with post-transplant lymphoproliferative disorder 
(PTLD) and endemic Burkitt’s lymphoma (BL) (Rickinson and Kieff 2007). PTLD 
and its in vitro experimental model, lymphoblastoid cell line (LCL), are associated 
with the most immunogenic form of latency (latency III) in which all EBV nuclear 
antigens (EBNA-1, -2, -LP, -3A, -3B and -3C) and latent membrane proteins (LMP-1, 
-2A and -2B) are expressed. Endemic BL can display either type I or Wp-restricted 
(~15% of the endemic BL) latency (Kelly, et al 2013). In type I latency, only EBNA-1 
is expressed. In Wp-restricted latency, EBNA-1, EBNA-LP, EBNA-3A, EBNA-3B 
and EBNA-3C are expressed (Rowe, et al 2009). BL cell lines can also switch to 
express latency III infection after long period of in vitro culture (Gregory, et al 1990). 
Most of the EBV latent proteins expressed in Wp-restricted or type III latency 
were shown to be oncogenic and might contribute to the resistance of EBV-associated 
lymphomas to standard chemotherapy. Leao et al. showed that EBV-positive BL cells 
of type III latency were more resistant to the killing by nocodazole or taxol in 
comparison to EBV-negative or latency I BL cells (Leao, et al 2007). Kelly et al. 
showed that Wp-restricted BL cells were also more resistant to the treatment with 
ionomycin or anti-IgM when compared with latency I BL cells (Kelly, et al 2005). 
Vereide et al. found that EBV conferred essential anti-apoptotic effects on both 
Wp-restricted BL and PTLD cells but not on latency I BL cells (Vereide and Sugden 
2011). EBNA-LP, -3A, -3B and -3C are expressed in both Wp-restricted and type III 
latency but not in type I latency (Rickinson and Kieff 2007). Among these viral latent 
proteins, EBNA-3A and EBNA-3C were shown to have anti-apoptotic functions in 
different B-cell malignancies. Tumour suppressor genes such as Bim, p16
INK4A
 and 
p21
WAF1
 are down-regulated by EBNA-3A or -3C through epigenetic modification of 
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the host cell genomes (Anderton, et al 2008, Cooper, et al 2003, Hertle, et al 2009, 
Maruo, et al 2006, Maruo, et al 2011, Paschos, et al 2009, Saha, et al 2011, Skalska, 
et al 2010). The epigenetic modification by the virus latent proteins could be achieved 
either through interaction with C-terminal binding protein or direct recruitment of 
histone deacetylases (HDAC) such as HDAC-1 and HDAC-2 (Chinnadurai 2002, 
Knight, et al 2003, Radkov, et al 1999, White, et al 2010). 
HDAC inhibitors can inhibit various types of HDAC enzymes and mediate 
potent anti-cancer effect in a wide range of malignancies. We have reported that an 
FDA-approved HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), can 
induce growth arrest and apoptosis of EBV-positive gastric carcinoma and 
nasopharyngeal carcinoma cells by disrupting the EBV latency (Hui and Chiang 2010, 
Hui, et al 2012). HDAC inhibitors can also induce the expression of Bim, p16
INK4A
 
and p21
WAF1
 (Gui, et al 2004, Zhou, et al 2009). The induction of apoptosis and 
up-regulation of tumour suppressor genes by HDAC inhibitors can be greatly 
enhanced when co-administered with proteasome inhibitors such as bortezomib 
(Emanuele, et al 2007, Heider, et al 2009, Hui and Chiang 2014, Pei, et al 2004, Yu, 
et al 2003). However, it remains unknown whether combination of HDAC and 
proteasome inhibitors can affect the expression of tumour suppressor genes and 
induce apoptosis of EBV-associated B-cell malignancies. 
In this study, we tested the hypothesis that combination of HDAC inhibitors (e.g. 
SAHA) and proteasome inhibitors (e.g. bortezomib) can synergistically induce 
apoptosis of Wp-restricted BL and LCLs. Our results showed that SAHA/bortezomib 
can preferentially induce the killing of Wp-restricted and latency III BL cells but not 
latency I BL cells. The synergistic killing can also be achieved in EBV-transformed 
LCLs which express type III latency. The synergism of SAHA/bortezomib is probably 
mediated through reversal of the suppressive effects of EBNA-3 proteins on p16
INK4A
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and p21
WAF1
 with subsequent induction of apoptosis in the Wp-restricted BL and 
LCLs. Furthermore, the drug combination can suppress the growth of Wp-restricted 
BL xenografts in vivo. Our findings provide the rationale to test the efficacy of 
SAHA/bortezomib in the treatment of Wp-restricted BL and primary EBV-driven 
lymphoproliferative diseases such as PTLD. 
 
Materials and Methods: 
Cell culture 
Akata 31 (Ak31) is an EBV-negative Burkitt’s lymphoma (BL) cell line. Akata 
2003 (Ak2003), Mutu-I, Daudi, P3HR1-c16, Raji and Mutu-III are EBV-positive BL 
cell lines (obtained from Prof. M. Allday and Prof. P. Farrell, Imperial College, UK). 
LCL330, LCL337 and LCL354 were established by immortalization of peripheral 
blood mononuclear cells (PBMCs) of paediatric post-transplant lymphoproliferative 
disorder (PTLD) patients with B95-8 strain of EBV. All the cell lines were cultured in 
RPMI medium1640 and supplemented with fetal bovine serum (FBS; 10% and 15% 
for BL cell lines and LCLs, respectively), 1% penicillin and streptomycin (Invitrogen, 
Carlsbad, CA) and were grown in a humidified incubator at 37°C with 5% CO2. 
 
Chemicals 
MS-275, apicidin, panobinostat, sodium butyrate and bortezomib were purchased 
from Selleck (Selleck Chemicals, Houston, TX). SAHA was purchased from Cayman 
(Cayman Chemicals, Ann Arbor, MI). N-acetyl-cysteine (NAC) was purchased from 
Sigma (Sigma-Aldrich, St. Louis, MO). 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay  
BL and LCLs (5 X 10
5
 cells/ml) were seeded in triplicates in 96-well plates and 
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treated with various concentrations of drugs for 24, 48 and 72 hr. MTT (Invitrogen, 
Carlsbad, CA) assay was performed and percentage of cell proliferation was 
calculated as previously described (Hui and Chiang 2010, Hui, et al 2012). Three 
independent experiments were performed for each MTT assay. 
 
Annexin V/propidium iodide (AV/PI) assay 
BL and LCLs (5 X 10
5
 cells/ml) were treated with combination of SAHA and 
bortezomib for 48 hr. The treated cells were stained with FITC-AV and propidium 
iodide (PI; BD Pharmingen
TM
, Heidelberg, Germany) and the percentage of 
AV/PI-positive cells was calculated as previously described (Hui, et al 2012, Hui, et 
al 2013). Two independent experiments were performed in each cell line. 
 
Cell cycle analysis 
BL cells or LCLs (5 X 10
5
 cells/ml) were treated with combination of SAHA and 
bortezomib for 12, 24 and 48 hr. The treated cells were subjected to cellular DNA 
content analysis by flow cytometry as previously described (Hui and Chiang 2010). 
Three independent experiments were performed in each cell line. 
 
Western blot analysis 
BL cells or LCLs (5 X 10
5
 cells/ml) were treated with various concentrations of 
drugs for 24, 48 and 72 hr. Protein from the cell cultures was extracted and western 
blot analysis was performed as previously described (Hui and Chiang 2010). EBV 
lytic proteins (Zta), acetylated histone (acetyl-H3), apoptotic proteins (PAPR and 
cleaved caspase-3) and α-tubulin were detected with the antibodies described 
previously (Hui, et al 2012). EBV latent proteins were detected with mouse 
anti-LMP1 monoclonal, rabbit anti-EBNA-1 polyclonal (Prof. Jaap Middeldorp, VU 
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University, Netherlands), rat anti-EBNA-2 monoclonal (Prof. Elisabeth Kremmer, 
Institute of Molecular Immunology, Germany) and sheep anti-EBNA-3A polyclonal 
antibodies (Exalpha Biologicals, Maynard, MA). EBV Bcl2 homologue BHRF1 was 
detected with mouse anti-BHRF1 monoclonal antibody (Millipore, Temecula, CA). 
Expression of tumour suppressor genes was detected with mouse anti-p16 monoclonal 
(BD Biosciences, San Jose, CA), rabbit anti-p21 and anti-Bim polyclonal antibodies 
(Cell Signaling Technology, Beverly, MA), respectively. At least 2 independent 
experiments were performed in each western blotting. 
 
Nude mice experiment 
Female BALB/c nude (nu/nu) mice were purchased at 5-6 weeks of age from 
the Laboratory Animal Unit (LAU), The University of Hong Kong. The mice 
were housed in LAU under a pathogen-free condition. All experiments were 
performed in accordance with the LAU guidelines and approved by the 
Committee on the Use of Live Animals in Teaching and Research (CULATR) of 
The University of Hong Kong. P3HR1-c16 (1 X 10
7
) cells were re-suspended in 200 
µl serum-free culture medium. The cells were subcutaneously injected at the right 
flanks of female BALB/c nude (nu/nu) mice at 6-7 weeks of age. When the tumours 
became palpable, 60 µg/kg bortezomib, 50 mg/kg SAHA or their combination 
dissolved in DMSO in 10 µl was administered to nude mice of the treatment group 
(n=5) by intraperitoneal (IP) injection 5 days per week for 4 weeks. Equal volume of 
DMSO was administered by IP injection to nude mice of the control group (n=5). The 
size and the weight of the tumours were measured as described previously (Hui, et al 
2012, Hui, et al 2013). 
 
Statistical analysis 
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Synergism of SAHA and bortezomib was analyzed with isobologram analysis 
and combination index (CI) calculation as described previously (Hui and Chiang 2014, 
Hui, et al 2013). Curves that lie under the additive isobole in isobologram suggest 
synergism and vice versa. CI<1, =1 and >1 represents synergy, additivity and 
antagonism, respectively. All statistical analyses were performed with GraphPad 
Prism Version 5.0 software. 
 
Results 
BL cells of Wp-restricted or type III latency were more resistant to the treatment with 
HDAC inhibitors than those of type I latency, independent of lytic cycle induction.  
We tested the effects of different HDAC inhibitors on proliferation of 
EBV-positive BL cells which express different forms of viral latency. BL cells of type 
I (AK2003 and Mutu-I), Wp-restricted (Daudi and P3HR1-c16) and type III (Raji and 
Mutu-III) latencies were treated with five different HDAC inhibitors, including 
MS-275, apicidin, panobinostat, suberoylanilide hydroxamic acid (SAHA) and 
sodium butyrate (NaB) for 24, 48 and 72 hr. The treated cells were analyzed for cell 
proliferation by MTT assay (only the results on SAHA were shown because similar 
anti-proliferation effects by the HDAC inhibitors were observed; Fig. 1a). According 
to the data, all these HDAC inhibitors could suppress the proliferation of BL cells in a 
dose- and time-dependent manner. Half maximal inhibitory concentration (IC50) 
values of the five HDAC inhibitors on the proliferation of BL cells at 48-hr time point 
were determined (Table 1). The IC50 values of HDAC inhibitors on BL cells of 
Wp-restricted (Daudi and P3HR1-c16) and type III (Raji and Mutu-III) latencies were 
higher than those of latency I (AK2003 and Mutu-I), suggesting that BL cells of 
Wp-restricted and type III latencies were more resistant to the treatment with HDAC 
inhibitors. Since HDAC inhibitors were shown to induce EBV lytic cycle in BL cells 
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(Ghosh, et al 2012), we also investigated whether the enhanced resistance to the 
treatment with HDAC inhibitors was related to the refractoriness of EBV lytic cycle 
induction in the Wp-restricted and latency III BL cells (only the results on SAHA 
were shown because similar ability of lytic cycle induction by the HDAC inhibitors 
were observed; Fig. 1b). We found that HDAC inhibitors could not induce the 
expression of Zta in almost all these BL cell lines (except weak induction was 
observed in P3HR1-c16) regardless of the forms of viral latency, indicating that the 
differential responses of the BL cell lines to killing by HDAC inhibitors were 
unrelated to EBV lytic cycle induction. Collectively, our data showed that 
Wp-restricted and latency III BL cells were more resistant to the treatment with 
HDAC inhibitors when compared with latency I BL cells and the drug resistance was 
independent of EBV lytic cycle induction. 
 
Combination of SAHA/bortezomib induced synergistic killing of Wp-restricted and 
latency III BL cells.  
Since combination of SAHA and bortezomib, a proteasome inhibitor, can 
synergistically induce cell death in various types of cancers (Emanuele, et al 2007, 
Hui, et al 2013, Pitts, et al 2009, Zhang, et al 2009), we also investigated the effect of 
combining SAHA/bortezomib on the killing of BL cell lines expressing various types 
of EBV latency. We treated latency I (AK2003 and Mutu-I), Wp-restricted (Daudi and 
P3HR1-c16) or latency III (Raji and Mutu-III) BL cells with combinations of various 
concentrations of SAHA (0, 0.125, 0.25, 0.5, 1 and 2 µM) and bortezomib (0, 1, 2, 4, 
8, 16, 32 and 64 nM). The treated cells were analyzed for cell proliferation by MTT 
assay (Fig. 2a). When compared with either drug alone, SAHA/bortezomib yielded a 
much stronger anti-proliferative effect in the Wp-restricted and latency III BL cells. 
However, such enhanced killing could not be observed in the latency I BL cells. 
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Isobologram analysis was performed to determine the synergism between 
SAHA/bortezomib (Fig. 2b). Whilst the isoboles lied to the left of the additive 
isoboles for the Wp-restricted and latency III BL cells, they lied to the right for the 
latency I BL cells, indicating synergism of SAHA/bortezomib in the BL cells of 
Wp-restricted or type III latency. The synergistic anti-proliferative effect of 
bortezomib and other HDAC inhibitors (including MS-275, apicidin, panobinostat 
and NaB) could also be observed in the Wp-restricted P3HR1-c16 cells 
(supplementary Fig. 1). 
 
Synergistic killing by SAHA/bortezomib could also be achieved in LCLs.  
To test whether the synergistic killing could also be observed in other 
EBV-associated B cell lines, we established a panel of EBV-transformed 
lymphoblastoid cell lines (LCLs), including LCL330, LCL337 and LCL354, from 
PBMCs of patients with post-transplant lymphoproliferative disorder (PTLD). 
According to the MTT assay and isobologram analysis, SAHA/bortezomib could also 
induce killing of all three LCLs synergistically (Fig. 3a). To confirm the EBV latency 
in the LCLs and BL cells, we examined the expression pattern of EBV latent proteins 
in the cell lines by western blot analysis. BL cells of type I latency, including 
AK2003 and Mutu-I only expressed EBNA-1 protein. The Wp-restricted BL cell lines, 
Daudi and P3HR1-c16, expressed EBNA-1 and the EBNA-3 proteins (here shown by 
EBNA-3A). BL cells and LCLs of type III latency, including Raji, Mutu-III, LCL330, 
LCL337 and LCL354, expressed EBNA-1, EBNA-2, EBNA-3A and LMP-1 (Fig. 3b). 
 
SAHA/bortezomib induced apoptosis of Wp-restricted BL cells and latency III LCLs.  
We postulated that SAHA/bortezomib could antagonize the function of 
EBNA-3 proteins and induce cell cycle arrest and apoptosis of Wp-restricted BL 
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cells and LCLs. P3HR1-c16 and LCL337 cells were treated with 
SAHA/bortezomib for 12, 24, 48 and 72 hr, stained with propidium iodide and 
subjected to flow cytometric analysis of the cell cycle (Fig. 4a and c). The data at 
72 hr were not suitable for cell cycle analysis because the majority of the cells 
underwent apoptosis following the drug treatment. Following treatment of 
P3HR1-c16 cells with the drugs for 24 hr, SAHA clearly arrested cell cycle at G1 
phase whereas both bortezomib and SAHA/bortezomib arrested similar 
percentages of cells at G2/M phase. In LCL337, SAHA, bortezomib and 
SAHA/bortezomib arrested similar percentages of cells at G1 phase. These data 
indicated no apparent additive or synergistic effect between SAHA and 
bortezomib on cell cycle arrest in both P3HR1-c16 and LCL337. We also 
analyzed the percentages of the sub-G1 populations, which represent the cells 
undergoing apoptosis (Fig. 4b & 4d). The percentages of sub-G1 populations 
increased over time from 12 hr to 72 hr in the cells treated with 
SAHA/bortezomib or either drug alone. At 48-hr time point, significantly higher 
percentages of sub-G1 populations was obser ed in the cells treated with 
SAHA/bortezomib (~37% and ~53% in P3HR1-c16 and LCL337, respectively) 
when compared with those treated with either drug alone. We confirmed the 
enhanced apoptosis by annexinV/propidium iodide (AV/PI) staining (Fig. 4e). 
Following 48 hr treatment with SAHA, bortezomib or SAHA/bortezomib, the 
percentages of apoptotic cells (AV+) increased to 17.1%, 20.0% and 58.5% in 
P3HR1-c16 and to 13.7%, 39.7% and 86.6% in LCL337, respectively. To further 
analyze the relationship between the cell cycle arrest and apoptosis, we 
performed time course experiments to investigate the kinetics of expression of 
several cell cycle and apoptotic markers following treatment with 
SAHA/bortezomib (Fig. 4f). Expression of apoptotic markers (cleaved PARP and 
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caspase-3) appeared at 4 hr and 8 hr in LCL337 and P3HR1-c16, respectively. 
However, there was no significant alternation of the protein levels of the cell cycle 
regulators (cyclin-D1, CDK4, cyclin-B1 and p-cdc2) in both cell lines until 24 hr 
when down-regulation of CDK4, cyclin-B1 and p-cdc2 was observed. The early 
activation of apoptotic markers in the cell lines suggested the existence of two 
cellular subpopulations in response to the treatment with SAHA/bortezomib, one 
sensitive to apoptosis and the other arresting in the cell cycle. 
 
SAHA/bortezomib induced the expression of p16
INK4A
 and p21
WAF1
, concomitant with 
the up-regulation of apoptotic markers.  
Tumour suppressor proteins, including Bim, p16
INK4A
 and p21
WAF1
, were shown 
to be down-regulated by EBNA-3 proteins, hence facilitating the growth of 
EBV-associated malignancies (Anderton, et al 2008, Cooper, et al 2003, Hertle, et al 
2009, Maruo, et al 2006, Maruo, et al 2011, Paschos, et al 2009, Saha, et al 2011). We 
investigated whether SAHA/bortezomib could increase the levels of these tumour 
suppressor proteins in Wp-restricted BL and LCLs. We treated P3HR1-c16 cells and 
LCL337 with combination of SAHA/bortezomib for 24 hr. The cell lysates of the 
treated cells were analyzed for expression of tumour suppressor proteins (p16
INK4A
, 
p21
WAF1
, p27 and Bim), apoptotic markers (PARP, cleaved PARP and cleaved 
caspase-3) and cell cycle regulatory proteins (cyclin-D1, CDK4, cyclin-B1 and p-cdc2) 
by western blotting (Fig. 5). When compared with either drug alone, 
SAHA/bortezomib significantly induced the expression of p16
INK4A
 and p21
WAF1
 but 
not p27 (Fig. 5a) nor Bim (Fig. 5b) in both P3HR1-c16 and LCL337 cells. 
Concomitantly, SAHA/bortezomib increased the expression of cleaved PARP and 
cleaved caspase-3 and decreased the expression of PARP, CDK4, cyclin-B1 and 
p-cdc2. The up-regulation of the apoptotic marks and down-regulation of cell 
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cycle markers were consistent with the data presented in Fig. 4f. Together, the 
data indicated that induction of apoptosis and down-regulation of cell cycle 
regulatory proteins mediated by SAHA/bortezomib might be related to the 
up-regulation of p16
INK4A
 and p21
WAF1
. 
 
Up-regulation of p16
INK4A
 and p21
WAF1
 and induction of apoptosis were dependent on 
the generation of reactive oxygen species (ROS).  
We and others have reported that SAHA/bortezomib could synergistically induce 
apoptosis of various types of cancer cells through an ROS-dependent mechanism 
(Denlinger, et al 2004, Heider, et al 2009, Heider, et al 2008, Hui, et al 2013, Pei, et 
al 2004, Yu, et al 2003). We postulated that SAHA/bortezomib could mediate a 
similar apoptotic mechanism in both Wp-restricted BL and LCLs. We pre-treated 
P3HR1-c16 and LCL337 with 12 mM N-acetyl cysteine (NAC), an ROS scavenger, 
for 1 hr before treatment with SAHA/bortezomib. Addition of NAC could 
significantly reduce the cleavage of PARP and caspase-3 in both P3HR1-c16 and 
LCL337 (Fig. 5c). Interestingly, NAC also significantly reduced the protein levels 
of p16
INK4A
 and p21
WAF1
 (Fig. 5d and supplementary Fig. 2). Taken together, the 
data showed that SAHA/bortezomib could induce the up-regulation of p16
INK4A
 
and p21
WAF1
 and apoptosis in Wp-restricted BL and LCLs via an 
ROS-dependent mechanism (Fig. 5e).  
 
SAHA/bortezomib significantly suppressed the growth of Wp-restricted BL xenografts 
in nude mice.  
Finally, we attempted to examine the in vivo effect of SAHA/bortezomib on 
growth suppression of Wp-restricted BL and LCL xenografts. However, only the 
xenografts of P3HR1-c16, but not LCLs, could grow in nude mice. The mice bearing 
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the P3HR1-c16 xenografts were treated with either DMSO (vehicle control) (n=5), 50 
mg/kg SAHA (n=5), 60 µg/kg bortezomib (n=5) or combination of 50 mg/kg SAHA 
and 60 µg/kg bortezomib (n=5) for 5 days per week over 15 days by intraperitoneal 
injection (Fig. 6a). Toxicity of either SAHA, bortezomib or their combination on nude 
mice was assessed by monitoring their weight (Fig. 6b). Despite weight loss of 
approximately 5%, no other noticeable toxicity was observed in the mice treated with 
SAHA/bortezomib or either drug alone. The growth of tumours was measured during 
the experimental period (Fig. 6c). On day 6 post-treatment, mean tumour volumes of 
mice treated with vehicle control, SAHA or bortezomib started to exceed that of the 
group treated by SAHA/bortezomib. At the end of experiment (day 15 post-treatment), 
the mean tumour volumes of mice treated with vehicle control, SAHA, bortezomib 
and SAHA/bortezomib were 4093 mm
3
, 2950 mm
3
, 2948 mm
3
, and 1048 mm
3
, 
respectively. Whilst either SAHA or bortezomib alone suppressed the growth of 
tumours, their combination mediated much stronger suppressive effect (P < 0.01) (Fig. 
6d). 
 
Discussion 
Epstein-Barr virus (EBV) latent proteins exert anti-apoptotic effects on 
Wp-restricted Burkitt’s lymphoma (BL) and lymphoblastoid cell line (LCL) through 
down-regulation of Bim, p16
INK4A
 and p21
WAF1
 (Anderton, et al 2008, Cooper, et al 
2003, Hertle, et al 2009, Maruo, et al 2006, Maruo, et al 2011, Paschos, et al 2009, 
Saha, et al 2011, White, et al 2010). Histone deacetylase (HDAC) inhibitors can 
synergize with proteasome inhibitors to up-regulate these tumour suppressor genes 
(Emanuele, et al 2007, Heider, et al 2009, Hui and Chiang 2014, Pei, et al 2004, Yu, 
et al 2003). In this study, we hypothesized that combination of HDAC and 
proteasome inhibitors could synergistically induce apoptosis of Wp-restricted BL and 
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LCL.  
We first tested the responses of six endemic BL cell lines, which expressed either 
type I, Wp-restricted or type III latency, to a panel of HDAC inhibitors. We found 
that both Wp-restricted and latency III BL cell lines displayed higher resistance to 
killing by HDAC inhibitors when compared to latency I BL cell lines (refer to Fig. 1 
& Table 1). Despite identical cellular background of Mutu-I (latency I) and 
Mutu-III (latency III) cell lines (Gregory, et al 1990), Mutu-III cells were more 
resistant to HDAC inhibitor-mediated killing when compared with Mutu-I cells, 
strongly implicating the involvement of EBV latent proteins in the mechanism of 
drug resistance. Among the latent genes, EBNA-LP, -3A, -3B and -3C are expressed 
in both Wp-restricted and type III EBV latency. However, both EBNA-LP and 
EBNA-3B are not essential for the growth transformation of LCLs (Rickinson and 
Kieff 2007). We speculated that EBNA-3A and -3C might contribute to the 
resistance of Wp-restricted BL cells to the killing effect of HDAC inhibitors 
(Anderton, et al 2008, Skalska, et al 2010). Since HDAC inhibitors were reported to 
induce EBV lytic cycle in BL cell lines, we also analyzed whether the expression of 
EBV lytic proteins might be involved in the drug resistance of Wp-restricted or 
latency III BL cells (Iwamoto, et al 2011, Jung, et al 2007, Rodriguez, et al 1999). We 
found that HDAC inhibitors could only induce low expression levels of EBV lytic 
proteins in P3HR1-c16 cells, but not in other BL cell lines (refer to Fig. 1). Indeed, we 
had shown that HDAC inhibitors preferentially induce EBV lytic cycle in 
EBV-positive epithelial rather than B-cell malignancies (Hui and Chiang 2010, Hui, et 
al 2012). The data implied that the mechanism of drug resistance of Wp-restricted or 
latency III BL cells was independent of EBV lytic cycle induction. 
Our laboratory and others had previously reported that proteasome inhibitors 
such as bortezomib could potentiate the anti-tumour effect of HDAC inhibitors such 
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as SAHA in various types of cancers (Emanuele, et al 2007, Hui, et al 2013, Miller, et 
al 2009, Zhang, et al 2009). Moreover, combination of HDAC and proteasome 
inhibitors can up-regulate tumour suppressor genes in different cancer cell lines 
(Emanuele, et al 2007, Heider, et al 2009, Hui and Chiang 2014, Pei, et al 2004, Yu, 
et al 2003). Here, we demonstrated that SAHA/bortezomib could synergistically 
induce killing of Wp-restricted (Daudi and P3HR1-c16) or latency III (Raji and 
Mutu-III) BL cells but not latency I BL lines (Ak2003 and Mutu-I). Interestingly, the 
drug combination could also induce synergistic killing of EBV-transformed LCLs 
which also express type III latency. The synergistic killing was due to apoptosis as 
evidenced by the higher percentage of annexin V-positive and sub-G1 populations and 
stronger cleavage of PARP and caspase-3. 
EBNA-3 proteins could provide anti-apoptotic effect through down-regulation of 
tumour suppressor genes, including Bim, p16
INK4A
 and p21
WAF1
 (Anderton, et al 2008, 
Cooper, et al 2003, Hertle, et al 2009, Maruo, et al 2006, Maruo, et al 2011, Paschos, 
et al 2009, Saha, et al 2011, White, et al 2010). We analyzed the expression level of 
Bim, p16
INK4A
 and p21
WAF1
 and the viral encoded Bcl2 homologue, BHRF1, upon 
treatment with SAHA/bortezomib and found that the drug combination could 
significantly up-regulate the expression of p16
INK4A
 and p21
WAF1
, but not Bim nor 
BHRF1. One potential pro-apoptotic effect of p16
INK4A
 and p21
WAF1
 was mediated 
by arresting cells at G1 or G2/M phases (Davis, et al 1998, Mandl-Weber, et al 
2010, Park, et al 2002, Wang, et al 2010). We did not observe such casual 
relationship between cell cycle arrest and enhanced apoptosis in both 
Wp-restricted BL and LCLs upon treatment with SAHA/bortezomib which 
seemed to briskly induce apoptosis of Wp-restricted BL and LCLs without arrest 
of the cell cycle. Indeed, p16
INK4A
 has been shown to preferentially induce 
apoptosis in proliferating cells rather than G1-arrested cells (Al-Mohanna, et al 
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2004, Minami, et al 2003). p21
WAF1 
can also directly promote apoptosis in 
different cancer cell lines through mechanisms involving the activation of TNF 
receptors or induction of pro-apoptotic protein, Bax (Abbas and Dutta 2009). In 
addition, the induction of apoptosis and up-regulation of p16
INK4A
 and p21
WAF1
 
by SAHA/bortezomib were reactive oxygen species (ROS)-dependent, which is 
consistent with previous findings that ROS generation induced the expression of 
p16
INK4A
 and p21
WAF1
 and triggered apoptosis of different cancer cell lines 
(Donadelli, et al 2006, Hui and Chiang 2014, Hui, et al 2013, Kim and Wong 2009, 
Luo, et al 2011). We further evaluated the effect of SAHA/bortezomib on 
Wp-restricted BL xenografts in nude mice and found that the drug combination 
significantly suppressed the growth of Wp-restricted BL xenografts in nude mice, 
indicating that the in vitro anti-tumour effect of SAHA/bortezomib could also be 
achieved in vivo. 
Collectively, our results proposed a novel synergistic action of 
SAHA/bortezomib in Wp-restricted BL and LCLs through the up-regulation of 
p16
INK4A
 and p21
WAF1
, in a ROS-dependent pathway and possibly reversing the 
suppressive effect of EBNA-3 proteins on these tumour suppressor proteins. The 
potential application of this drug regimen as an alternative clinical regimen for 
the treatment of Wp-restricted BL and PTLD should be further investigated. 
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Figure legends: 
Fig 1. Effects of SAHA on proliferation of EBV-positive BL cells and induction of 
EBV lytic cycle. (A) EBV-positive BL cells of type I (AK2003 and Mutu-I), 
Wp-restricted (Daudi and P3HR1-c16) or type III latency (Raji and Mutu-III) were 
treated with increasing concentrations of SAHA for 24, 48 and 72 hr. Cell 
proliferation was measured by MTT reduction assay and presented as percentages of 
cell proliferation of treated cells compared with those of untreated cells. Error bars 
represent the standard error of mean (SEM) of data obtained in at least three 
independent experiments. (B) The cellular and viral proteins of BL cells treated with 
increasing concentrations of SAHA for 48 hr were extracted and analyzed for 
expression of an acetylated cellular histone H3 protein, acetyl-H3, and a viral lytic 
protein, Zta, by western blotting. α-tubulin was detected as a loading control. 
Anti-human IgG antibody (IgG) was used to induce the lytic cycle of AK2003 cells 
(AK03+IgG) and the protein extracted was loaded as a positive control of Zta 
expression. 
 
Fig 2. Effects of SAHA/bortezomib on proliferation of EBV-positive BL cells. (A) 
EBV-positive BL cells of type I (AK2003 and Mutu-I), Wp-restricted (Daudi and 
P3HR1-c16) or type III latency (Raji and Mutu-III) were treated with various 
combinations of SAHA (0, 0.125, 0.25, 0.5, 1, and 2 µM) and bortezomib (0, 1, 2, 4, 8, 
16, 32, and 64 nM) for 48 hr. Cell proliferation was determined by MTT assay and 
presented as percentages of cell proliferation of treated cells compared with those of 
untreated cells. Error bars represent the standard error of mean (SEM) of data 
obtained in at least three independent experiments. (B) Synergisms of 
proliferation inhibition of different BL cell lines were analyzed by isobologram 
analysis.  
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Fig 3. Effects of SAHA/bortezomib on proliferation of EBV-transformed LCLs. (A) 
Three EBV-transformed LCLs, including LCL330, LCL337 and LCL354, were 
treated with various combinations of SAHA (0, 0.125, 0.25, 0.5, 1, and 2 µM) and 
bortezomib (0, 1, 2, 4, 8, 16, 32, and 64 nM) for 48 hr. Cell proliferation was 
determined by MTT assay. Error bars represent the standard error of mean (SEM) 
of data obtained in at least three independent experiments. (B) Isobologram 
analysis was performed to analyze the synergism of SAHA and bortezomib on the 
LCLs. (C) Cellular proteins of six BL cell lines and three LCLs were extracted and 
analyzed for expression of EBV latent proteins including EBNA-1, EBNA-2, 
EBNA-3A and LMP-1 by western blotting. α-tubulin was detected as a loading 
control. EBV-negative sub-clone of Akata cells, AK31, was used as a negative 
control. 
 
Fig 4. Effects of SAHA/bortezomib on cell cycle arrest and apoptosis of 
Wp-restricted BL and LCLs. P3HR1-c16 and LCL337 were treated with combination 
of SAHA (2 µM and 1 µM for P3HR1-c16 and LCL337, respectively) and bortezomib 
(8 nM) or either drug alone for 12, 24, 48 and 72 hr. Cell cycle status was analyzed 
by flow cytometry and representative figures for (A) P3HR1-c16 and (C) 
LCL337 at 12, 24 and 48 hr are shown. The percentages of sub-G1 population of 
(B) P3HR1-c16 and (D) LCL337 at 12, 24, 48 and 72 hr are shown. The results 
were analyzed for statistical significance using One-way ANOVA Dunnett’s 
Multiple Comparison Test. P value less than 0.05 was considered statistically 
significant; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with 
SAHA/bortezomib. Error bars represent the standard error of mean (SEM) of data 
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obtained in at least three independent experiments. (E) Annexin V/propidium iodide 
(AV/PI) staining was performed to analyze for the percentages of apoptotic cells upon 
treatment with SAHA/bortezomib or either drug alone for 48 hr. AV+/PI- population 
represents early apoptotic cells whilst AV+/PI+ population represents late apoptotic/ 
necrotic cells. (F) P3HR1-c16 and LCL337 were treated with combination of 
SAHA (2 µM and 1 µM for P3HR1-c16 and LCL337, respectively) and 
bortezomib (8 nM) for 0, 2, 4, 8, 12 and 24 hr. The cellular proteins were 
extracted and analyzed for expression of PARP, cleaved PARP, cleaved caspase-3, 
cyclin-D1, CDK4, cyclin-B1 and p-cdc2 by western blot analysis. α-tubulin was 
detected as a loading control. 
 
Fig 5. The roles of p16
INK4A
, p21
WAF1
 and ROS in the apoptosis of Wp-restricted BL 
and LCLs. P3HR1-c16 and LCL337 were treated with combination of SAHA (2 µM 
and 1 µM for P3HR1-c16 and LCL337, respectively) and bortezomib (8 nM) or either 
drug alone for 24 hr. (A) The cellular proteins were extracted and analyzed for 
expression of p16
INK4A
, p21
WAF1
, p27, PARP, cleaved PARP, cleaved caspase-3, 
cyclin-D1, CDK4, cyclin-B1 and p-cdc2 by western blot analysis. α-tubulin was 
detected as a loading control. (B) Expression of the cellular pro-apoptotic protein Bim, 
viral latent protein EBNA-3A and viral encoded Bcl2 homologue BHRF1 was 
analyzed. (C) P3HR1-c16 cells and LCL337 were pretreated with N-acetyl cysteine 
(NAC) for 1 hr followed by treatment with SAHA, bortezomib or SAHA/bortzomib 
for 24 hr. Expression of PAPR, cleaved PARP and cleaved caspase-3 proteins was 
analyzed. (D) Expression of p16
INK4A
 and p21
WAF1
 proteins was analyzed. (E) 
Schematic diagram illustrating the roles of p16
INK4A
, p21
WAF1
 and ROS in the 
mechanism of apoptosis induced by SAHA/bortezomib. 
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Fig 6. Effects of SAHA/bortezomib on growth of Wp-restricted BL xenografts 
established in nude mice. P3HR1-c16 cells were inoculated into the right flanks of 
nude mice. The mice were treated with either DMSO (vehicle control) (n=5), 50 
mg/kg SAHA (n=5), 60 µg/kg bortezomib (n=5) or combination of 50 mg/kg SAHA 
and 60 µg/kg bortezomib (n=5) for 5 days per week over 15 days by intraperitoneal 
injection. (A) The tumours were resected from the nude mice at the end of the 
experiment. (B) The mice were weighed at 0, 1, 6, 8, 12 and 15 days post-treatment. 
(C) Tumour size measurements were performed at 0, 1, 6, 8, 12 and 15 days 
post-treatment by using a caliper. (D) Average tumour masses of mice of control and 
treated groups were shown. The results were analyzed for statistical significance using 
One-way ANOVA Dunnett’s Multiple Comparison Test. P value less than 0.05 was 
considered statistically significant; *P < 0.05, **P < 0.01, and ***P < 0.001 compared 
with SAHA/bortezomib. Error bars represent the standard error of mean (SEM) of 
data obtained from the nude mice (n=5). 
 
Supplementary Fig 1. Effects of combination of either MS-275, apicidin, SAHA or 
sodium butyrate (NaB) with bortezomib on proliferation of Wp-restricted BL cells. 
P3HR1-c16 cells were treated with combination of either MS-275 (0, 0.5, 1, 2, 4 and 
8 µM), apicidin (0, 31.25, 62.5, 125, 250 and 500 nM), panobinstat (0, 3.125, 6.25, 
12.5, 25 and 50 nM), or NaB (0, 0.6, 1.2, 2.4, 4.8 and 9.6 mM) and bortezomib (0, 1, 
2, 4, 8, 16, 32, and 64 nM) for 48 hr. Cell proliferation was determined by MTT assay 
and presented as percentages of cell proliferation of treated cells compared with those 
of untreated cells. Synergisms of proliferation inhibition of the cells following 
treatment with different drug combinations were analyzed by isobologram analysis. 
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Supplementary Fig 2. Western blot results in Fig. 4d were quantitated by 
densitometry. The bars represent the relative protein levels compared to the 
loading control. 
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Fig 1. Effects of SAHA on proliferation of EBV-positive BL cells and induction of EBV lytic cycle. (A) EBV-
positive BL cells of type I (AK2003 and Mutu-I), Wp-restricted (Daudi and P3HR1-c16) or type III latency 
(Raji and Mutu-III) were treated with increasing concentrations of SAHA for 24, 48 and 72 hr. Cell 
proliferation was measured by MTT reduction assay and presented as percentages of cell proliferation of 
treated cells compared with those of untreated cells. Error bars represent the standard error of mean (SEM) 
of data obtained in at least three independent experiments. (B) The cellular and viral proteins of BL cells 
treated with increasing concentrations of SAHA for 48 hr were extracted and analyzed for expression of an 
acetylated cellular histone H3 protein, acetyl-H3, and a viral lytic protein, Zta, by western blotting. α-tubulin 
was detected as a loading control. Anti-human IgG antibody (IgG) was used to induce the lytic cycle of 
AK2003 cells (AK03+IgG) and the protein extracted was loaded as a positive control of Zta expression.  
206x237mm (300 x 300 DPI)  
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HDAC inhibitor MS-275 
(µM) 
Apicidin 
(nM) 
Panobinostat 
(nM) 
SAHA 
(µM) 
NaB 
(mM) 
Cell line Latency 
AK2003 I 0.37 90.79 4.51 0.55 0.49 
Mutu-I I 0.70 78.48 4.65 0.26 0.40 
Daudi Wp 0.80 501.70 17.28 1.72 1.56 
P3HR1-c16 Wp 11.29 684.3 33.47 1.84 5.57 
Raji III 5.61 1220.00 33.28 1.31 10.57 
Mutu-III III 3.90 971.70 75.71 3.73 7.74 
 
Table 1. Values of half maximal inhibitory concentration (IC50) of HDAC 
inhibitors on proliferation of BL cells 
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Fig 2. Effects of SAHA/bortezomib on proliferation of EBV-positive BL cells. (A) EBV-positive BL cells of type I 
(AK2003 and Mutu-I), Wp-restricted (Daudi and P3HR1-c16) or type III latency (Raji and Mutu-III) were 
treated with various combinations of SAHA (0, 0.125, 0.25, 0.5, 1, and 2 µM) and bortezomib (0, 1, 2, 4, 8, 
16, 32, and 64 nM) for 48 hr. Cell proliferation was determined by MTT assay and presented as percentages 
of cell proliferation of treated cells compared with those of untreated cells. Error bars represent the standard 
error of mean (SEM) of data obtained in at least three independent experiments. (B) Synergisms of 
proliferation inhibition of different BL cell lines were analyzed by isobologram analysis.  
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Fig 3. Effects of SAHA/bortezomib on proliferation of EBV-transformed LCLs. (A) Three EBV-transformed 
LCLs, including LCL330, LCL337 and LCL354, were treated with various combinations of SAHA (0, 0.125, 
0.25, 0.5, 1, and 2 µM) and bortezomib (0, 1, 2, 4, 8, 16, 32, and 64 nM) for 48 hr. Cell proliferation was 
determined by MTT assay. Error bars represent the standard error of mean (SEM) of data obtained in at 
least three independent experiments. (B) Isobologram analysis was performed to analyze the synergism of 
SAHA and bortezomib on the LCLs. (C) Cellular proteins of six BL cell lines and three LCLs were extracted 
and analyzed for expression of EBV latent proteins including EBNA-1, EBNA-2, EBNA-3A and LMP-1 by 
western blotting. α-tubulin was detected as a loading control. EBV-negative sub-clone of Akata cells, AK31, 
was used as a negative control.  
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Fig 4. Effects of SAHA/bortezomib on cell cycle arrest and apoptosis of Wp-restricted BL and LCLs. P3HR1-
c16 and LCL337 were treated with combination of SAHA (2 µM and 1 µM for P3HR1-c16 and LCL337, 
respectively) and bortezomib (8 nM) or either drug alone for 12, 24, 48 and 72 hr. Cell cycle status was 
analyzed by flow cytometry and representative figures for (A) P3HR1-c16 and (C) LCL337 at 12, 24 and 48 
hr are shown. The percentages of sub-G1 population of (B) P3HR1-c16 and (D) LCL337 at 12, 24, 48 and 72 
hr are shown. The results were analyzed for statistical significance using One-way ANOVA Dunnett’s Multiple 
Comparison Test. P value less than 0.05 was considered statistically significant; *P < 0.05, **P < 0.01, and 
***P < 0.001 compared with SAHA/bortezomib. Error bars represent the standard error of mean (SEM) of 
data obtained in at least three independent experiments. (E) Annexin V/propidium iodide (AV/PI) staining 
was performed to analyze for the percentages of apoptotic cells upon treatment with SAHA/bortezomib or 
either drug alone for 48 hr. AV+/PI- population represents early apoptotic cells whilst AV+/PI+ population 
represents late apoptotic/ necrotic cells. (F) P3HR1-c16 and LCL337 were treated with combination of SAHA 
(2 µM and 1 µM for P3HR1-c16 and LCL337, respectively) and bortezomib (8 nM) for 0, 2, 4, 8, 12 and 24 
hr. The cellular proteins were extracted and analyzed for expression of PARP, cleaved PARP, cleaved 
caspase-3, cyclin-D1, CDK4, cyclin-B1 and p-cdc2 by western blot analysis. α-tubulin was detected as a 
loading control.  
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Fig 5. The roles of p16INK4A, p21WAF1 and ROS in the apoptosis of Wp-restricted BL and LCLs. P3HR1-c16 
and LCL337 were treated with combination of SAHA (2 µM and 1 µM for P3HR1-c16 and LCL337, 
respectively) and bortezomib (8 nM) or either drug alone for 24 hr. (A) The cellular proteins were extracted 
and analyzed for expression of p16INK4A, p21WAF1, p27, PARP, cleaved PARP, cleaved caspase-3, cyclin-
D1, CDK4, cyclin-B1 and p-cdc2 by western blot analysis. α-tubulin was detected as a loading control. (B) 
Expression of the cellular pro-apoptotic protein Bim, viral latent protein EBNA-3A and viral encoded Bcl2 
homologue BHRF1 was analyzed. (C) P3HR1-c16 cells and LCL337 were pretreated with N-acetyl cysteine 
(NAC) for 1 hr followed by treatment with SAHA, bortezomib or SAHA/bortzomib for 24 hr. Expression of 
PAPR, cleaved PARP and cleaved caspase-3 proteins was analyzed. (D) Expression of p16INK4A and 
p21WAF1 proteins was analyzed. (E) Schematic diagram illustrating the roles of p16INK4A, p21WAF1 and 
ROS in the mechanism of apoptosis induced by SAHA/bortezomib.  
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Fig 6. Effects of SAHA/bortezomib on growth of Wp-restricted BL xenografts established in nude mice. 
P3HR1-c16 cells were inoculated into the right flanks of nude mice. The mice were treated with either DMSO 
(vehicle control) (n=5), 50 mg/kg SAHA (n=5), 60 µg/kg bortezomib (n=5) or combination of 50 mg/kg 
SAHA and 60 µg/kg bortezomib (n=5) for 5 days per week over 15 days by intraperitoneal injection. (A) The 
tumours were resected from the nude mice at the end of the experiment. (B) The mice were weighed at 0, 
1, 6, 8, 12 and 15 days post-treatment. (C) Tumour size measurements were performed at 0, 1, 6, 8, 12 
and 15 days post-treatment by using a caliper. (D) Average tumour masses of mice of control and treated 
groups were shown. The results were analyzed for statistical significance using One-way ANOVA Dunnett’s 
Multiple Comparison Test. P value less than 0.05 was considered statistically significant; *P < 0.05, **P < 
0.01, and ***P < 0.001 compared with SAHA/bortezomib. Error bars represent the standard error of mean 
(SEM) of data obtained from the nude mice (n=5).  
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Supplementary Fig 1. Effects of combination of either MS-275, apicidin, SAHA or sodium butyrate (NaB) with 
bortezomib on proliferation of Wp-restricted BL cells. P3HR1-c16 cells were treated with combination of 
either MS-275 (0, 0.5, 1, 2, 4 and 8 µM), apicidin (0, 31.25, 62.5, 125, 250 and 500 nM), panobinstat (0, 
3.125, 6.25, 12.5, 25 and 50 nM), or NaB (0, 0.6, 1.2, 2.4, 4.8 and 9.6 mM) and bortezomib (0, 1, 2, 4, 8, 
16, 32, and 64 nM) for 48 hr. Cell proliferation was determined by MTT assay and presented as percentages 
of cell proliferation of treated cells compared with those of untreated cells. Synergisms of proliferation 
inhibition of the cells following treatment with different drug combinations were analyzed by isobologram 
analysis.  
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Supplementary Fig 2. Western blot results in Fig. 4d were quantitated by densitometry. The bars represent 
the relative protein levels compared to the loading control.  
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